Healthy Japanese
Conditions
Interventions
Duration: Eight weeks Test product: Soft capsule containing PapriX(R) (xanthophyll derived from red bell pepper) Administration: Consume one capsule per day with water at dinner. *If a dose is mi
Sponsors
Glico Nutrition Co., Ltd.
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Japanese 2. Men or women 3. Adults 4. Healthy individuals 5. Individuals whose TEWL (arm) is high at screening (Scr)
Exclusion criteria
Exclusion criteria: 1. Individuals who are undergoing medical treatment or have a medical history of malignant tumor, heart failure, or myocardial infarction 2. Individuals who have a pacemaker or an implantable cardioverter defibrillator (ICD) 3. Individuals who are currently undergoing treatment for any of the following chronic diseases: cardiac arrhythmia, liver disorder, chronic kidney disease, cerebrovascular disorder, rheumatic disease, diabetes mellitus, dyslipidemia, hypertension, or any other chronic diseases 4. Individuals who are taking "Foods for Specified Health Uses" or "Foods with Functional Claims" 5. Individuals who are taking medicines (including herbal medicines) or supplements 6. Individuals who have been diagnosed with atopic dermatitis 7. Individuals who use any products except for cosmetic creams, beauty essence, all-in-one cosmetic makeup, face masks, skin lotions, milky lotions, and sunscreen for daily skincare 8. Individuals who habitually receive skincare treatment (e.g., aesthetic treatment) or use instruments for beauty treatment (e.g., facial treatment device) 9. Individuals who have undergone cosmetic surgery 10. Individuals who are allergic to medicines or foods related to the test product (particularly, green pepper or bell pepper) 11. Individuals who are pregnant, lactating, or planning to become pregnant during this study 12. Individuals who have been enrolled in other clinical studies within the last 28 days before the agreement to participate in this study or plan to participate in another study during this study 13. Individuals who receive hormone replacement therapy 14. Individuals whose lifestyle may majorly change (such as long-term travel) during this study 15. Individuals who are judged as ineligible to participate in this study by the physician
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. The measured value of transepidermal water loss (TEWL) (left forearm) at 8 weeks after intervention (8w) | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. The measured values of TEWL (right cheek), the moisture content of skin (right cheek), the moisture content of skin (left forearm), skin viscoelasticity (R0~R9) (right cheek) and skin viscoelasticity (R0~R7) (left forearm) at 8w 2. The measured values of TEWL (left forearm), TEWL (right cheek), the moisture content of skin (right cheek), the moisture content of skin (left forearm), skin viscoelasticity (R0~R9) (right cheek) and skin viscoelasticity (R0~R7) (left forearm) at 4 weeks after intervention (4w) 3. Skin moisture, skin texture, sagging of the skin, skin elasticity, skin viscoelasticity, skin glow, skin brightness, skindex-16 total score, questions about symptoms (item 1~4), questions about emotions (item 5~11), questions about functioning (item 12~16) and each item in skindex-16 at 4w and 8w. | — |
Countries
Japan
Contacts
Public ContactNaoko Suzuki
ORTHOMEDICO Inc. R&D Department
Outcome results
None listed